JP2687995B2
(ja)
|
1980-04-03 |
1997-12-08 |
バイオゲン インコーポレイテッド |
Dna配列、組替えdna分子およびヒト繊維芽細胞インターフェロン様ポリペプチドの製造方法
|
IT1185503B
(it)
*
|
1984-01-11 |
1987-11-12 |
Univ New York |
Cloni di odna di eritropietina umana
|
JPS62501010A
(ja)
|
1984-12-04 |
1987-04-23 |
ジェネティックス・インスチチュ−ト・インコ−ポレ−テッド |
エリトロポエチンの生産方法
|
IL77081A
(en)
*
|
1984-12-04 |
1999-10-28 |
Genetics Inst |
AND sequence encoding human erythropoietin, a process for its preparation and a pharmacological preparation of human erythropoietin
|
US4677195A
(en)
*
|
1985-01-11 |
1987-06-30 |
Genetics Institute, Inc. |
Method for the purification of erythropoietin and erythropoietin compositions
|
US4745099A
(en)
*
|
1985-02-06 |
1988-05-17 |
Chugai Seiyaku Kabushiki Kaisha |
Pharmaceutical composition for the treatment of the anemia of malignant tumors
|
US4732889A
(en)
*
|
1985-02-06 |
1988-03-22 |
Chugai Seiyaku Kabushiki Kaisha |
Pharmaceutical composition for the treatment of the anemia of rheumatoid arthritis
|
GB2177914B
(en)
*
|
1985-06-04 |
1989-10-25 |
Chugai Pharmaceutical Co Ltd |
A pharmaceutical composition containing human erythropoietin and a surface active agent for nasal administration for the treatment of anemia
|
IL79176A
(en)
*
|
1985-06-20 |
1992-06-21 |
Kirin Amgen Inc |
Process for the recovery of erythropoietin from a fluid
|
US4810643A
(en)
*
|
1985-08-23 |
1989-03-07 |
Kirin- Amgen Inc. |
Production of pluripotent granulocyte colony-stimulating factor
|
US6004548A
(en)
*
|
1985-08-23 |
1999-12-21 |
Amgen, Inc. |
Analogs of pluripotent granulocyte colony-stimulating factor
|
JPS63500636A
(ja)
*
|
1985-08-23 |
1988-03-10 |
麒麟麦酒株式会社 |
多分化能性顆粒球コロニー刺激因子をコードするdna
|
US4935350A
(en)
*
|
1985-11-18 |
1990-06-19 |
Amgen |
Materials and methods for controlling plasmid copy number and stability
|
JPS62171696A
(ja)
*
|
1986-01-23 |
1987-07-28 |
Sumitomo Chem Co Ltd |
ヒトエリスロポエチンの製造方法
|
DE3789678T2
(de)
*
|
1986-02-27 |
1994-08-11 |
Snow Brand Milk Prod Co Ltd |
Herstellung von erythropoietinproduzierenden Zellen und Verfahren zur Herstellung von Erythropoietin mit Verwendung dieser Zellen.
|
DK173067B1
(da)
|
1986-06-27 |
1999-12-13 |
Univ Washington |
Humant erythropoietin-gen, fremgangsmåde til ekspression deraf i transficerede cellelinier, de transficerede cellelinier sa
|
GR871029B
(en)
|
1986-07-14 |
1987-11-02 |
Genetics Inst |
Novel osteoinductive factors
|
US4954437A
(en)
*
|
1986-09-15 |
1990-09-04 |
Integrated Genetics, Inc. |
Cell encoding recombinant human erythropoietin
|
US5013718A
(en)
*
|
1986-11-21 |
1991-05-07 |
Amgen, Inc. |
Method for treating iron overload using EPO
|
WO1988005466A2
(en)
*
|
1987-01-15 |
1988-07-28 |
Codon |
Tandem gene eukaryotic expression vectors
|
US4835260A
(en)
*
|
1987-03-20 |
1989-05-30 |
Genetics Institute, Inc. |
Erythropoietin composition
|
JP2791418B2
(ja)
|
1987-12-02 |
1998-08-27 |
株式会社ミドリ十字 |
異種蛋白質の製造方法、組換えdna、形質転換体
|
DE3923963A1
(de)
*
|
1989-07-20 |
1991-01-31 |
Behringwerke Ag |
Muteine des menschlichen erythropoetins, ihre herstellung und ihre verwendung
|
DE3924746A1
(de)
*
|
1989-07-26 |
1991-01-31 |
Behringwerke Ag |
Erythropoietin (epo)-peptide und dagegen gerichtete antikoerper
|
US6932968B1
(en)
|
1989-07-26 |
2005-08-23 |
Dade Behring Marburg Gmbh |
Erythropoietin (EPO) peptides and antibodies directed against these
|
US7217689B1
(en)
|
1989-10-13 |
2007-05-15 |
Amgen Inc. |
Glycosylation analogs of erythropoietin
|
KR100263845B1
(ko)
*
|
1989-10-13 |
2000-08-16 |
스튜어트 엘.왓트 |
에리트로포이에틴 동형체와 그의 제조방법 및 그를 포함하는제약학적 조성물
|
DE4115722A1
(de)
*
|
1991-05-14 |
1992-11-19 |
Boehringer Mannheim Gmbh |
Serumfreies medium zur kultivierung von saeugerzellen
|
US5968502A
(en)
*
|
1991-11-05 |
1999-10-19 |
Transkaryotic Therapies, Inc. |
Protein production and protein delivery
|
NZ245015A
(en)
*
|
1991-11-05 |
1995-12-21 |
Transkaryotic Therapies Inc |
Delivery of human growth hormone through the administration of transfected cell lines encoding human growth hormone, which are physically protected from host immune response; the transfected cells and their production
|
US6270989B1
(en)
|
1991-11-05 |
2001-08-07 |
Transkaryotic Therapies, Inc. |
Protein production and delivery
|
US5728536A
(en)
*
|
1993-07-29 |
1998-03-17 |
St. Jude Children's Research Hospital |
Jak kinases and regulation of Cytokine signal transduction
|
FR2686899B1
(fr)
*
|
1992-01-31 |
1995-09-01 |
Rhone Poulenc Rorer Sa |
Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
|
US6670178B1
(en)
|
1992-07-10 |
2003-12-30 |
Transkaryotic Therapies, Inc. |
In Vivo production and delivery of insulinotropin for gene therapy
|
US6531124B1
(en)
|
1992-07-10 |
2003-03-11 |
Transkaryotic Therapies, Inc. |
In vivo production and delivery of insulinotropin for gene therapy
|
WO1994005679A1
(en)
*
|
1992-09-09 |
1994-03-17 |
Nippon Kayaku Kabushiki Kaisha |
Novel physiologically active substance nk175203, process for producing the same, and pharmaceutical use thereof
|
AU6709794A
(en)
*
|
1993-04-21 |
1994-11-08 |
Brigham And Women's Hospital |
Erythropoietin muteins with enhanced activity
|
ZA946122B
(en)
*
|
1993-08-17 |
1995-03-20 |
Amgen Inc |
Erythropoietin analogs
|
US8192955B1
(en)
*
|
1994-01-03 |
2012-06-05 |
Genentech, Inc. |
Nucleic acids encoding MPL ligand (thrombopoietin), variants, and fragments thereof
|
US5888774A
(en)
*
|
1994-12-19 |
1999-03-30 |
Cangene Corporation |
Recombinant DNA molecules and expression vectors for erythropoietin
|
IL118201A
(en)
*
|
1995-05-11 |
2004-12-15 |
Roche Diagnostics Gmbh |
Preparation comprising a protein with human erythropoietin activity which is free of serum and non-recombinant mammalian protein and process for the preparation thereof
|
EP1510524A3
(en)
*
|
1995-06-07 |
2006-06-07 |
Ortho Pharmaceutical Corporation |
Compounds and peptides that bind to the erythropoietin receptor
|
ES2333425T5
(es)
|
1995-06-15 |
2012-08-28 |
Crucell Holland B.V. |
Sistemas de empaquetado para adenovirus recombinante humano destinados a terapia génica
|
EP0752474A1
(en)
*
|
1995-07-07 |
1997-01-08 |
Boehringer Mannheim Gmbh |
Nucleic acid coding for CMP-N-acetyl-neuraminic acid hydroxylase and its use for the production of modified glycoproteins
|
EP0837942A1
(en)
*
|
1995-07-07 |
1998-04-29 |
Boehringer Mannheim Gmbh |
Nucleic acid coding for cmp-n-acetyl-neuraminic acid hydroxylase and its use for the production of modified glycoproteins
|
CA2246768C
(en)
|
1996-03-14 |
2013-12-31 |
Genentech, Inc. |
Uses of gdnf and gdnf receptor
|
GB2318352A
(en)
*
|
1996-06-25 |
1998-04-22 |
Dejan Markovic |
Polypeptides mimicking the activity of human erythropoietin
|
US5952226A
(en)
*
|
1996-11-05 |
1999-09-14 |
Modex Therapeutiques |
Hypoxia responsive EPO producing cells
|
EP0975673A2
(en)
*
|
1997-04-21 |
2000-02-02 |
Glycozyme, Inc. |
Determination of recombinant glycosylated proteins and peptides in biological fluids
|
US6475725B1
(en)
|
1997-06-20 |
2002-11-05 |
Baxter Aktiengesellschaft |
Recombinant cell clones having increased stability and methods of making and using the same
|
DE19729769A1
(de)
|
1997-07-11 |
1999-01-14 |
Cardiogene Gentherapeutische S |
Transfektionssystem, seine Herstellung und Verwendung in der somatischen Gentherapie
|
US6017876A
(en)
|
1997-08-15 |
2000-01-25 |
Amgen Inc. |
Chemical modification of granulocyte-colony stimulating factor (G-CSF) bioactivity
|
US6897066B1
(en)
*
|
1997-09-26 |
2005-05-24 |
Athersys, Inc. |
Compositions and methods for non-targeted activation of endogenous genes
|
US6740503B1
(en)
|
1997-09-26 |
2004-05-25 |
Athersys, Inc. |
Compositions and methods for non-targeted activation of endogenous genes
|
ATE489461T1
(de)
*
|
1997-10-16 |
2010-12-15 |
Univ Georgia |
Transgene vögel und proteinproduktion
|
EP1037927B1
(en)
|
1997-12-08 |
2004-05-19 |
Lexigen Pharmaceuticals Corp. |
Heterodimeric fusion proteins useful for targeted immune therapy and general immune stimulation
|
BR9908096A
(pt)
*
|
1998-02-19 |
2000-10-31 |
Eastern Virginia Med School |
Proteìna 3 da zona pelúcida humana (hzp3), ativa, recombinante
|
US7037663B2
(en)
*
|
1998-02-19 |
2006-05-02 |
Eastern Virginia Medical School |
Human zona pellucida protein 3 and uses thereof
|
ES2224299T3
(es)
|
1998-02-23 |
2005-03-01 |
Cilag Ag International |
Dispersion liposomal de eritroyetina.
|
US20030105294A1
(en)
*
|
1998-02-25 |
2003-06-05 |
Stephen Gillies |
Enhancing the circulating half life of antibody-based fusion proteins
|
KR100434729B1
(ko)
*
|
1998-03-18 |
2004-11-03 |
주식회사 엘지생명과학 |
천연 추출물을 첨가하여 중국햄스터 난소 유래세포에서 에리스로포이에틴의 생산 증대방법
|
CA2325564A1
(en)
*
|
1998-03-27 |
1999-10-07 |
Cytos Biotechnology Ag |
Inducible alphaviral gene expression system
|
AR019025A1
(es)
|
1998-04-09 |
2001-12-26 |
Roche Diagnostics Gmbh |
Uso de eritropoyetina en bajas dosis para producir un preparado farmaceutico para el tratamiento de hemocromatosis, preparado farmaceutico combinadoutilizado segun dicho uso y envase farmaceutico unitario que contiene al referido preparado farmaceutico combinado
|
ES2267263T3
(es)
*
|
1998-04-15 |
2007-03-01 |
Emd Lexigen Research Center Corp. |
Coadministracion de un inhibidor de la angiogenesis para reforzar la respuesta inmunologica por medio de la mediacion de una proteina de fusion de una citoquina con un anticuerpo.
|
US6696411B1
(en)
*
|
1998-04-22 |
2004-02-24 |
Cornell Research Foundation, Inc. |
Canine erythropoietin gene and recombinant protein
|
EP1071795A4
(en)
|
1998-04-22 |
2005-01-19 |
Cornell Res Foundation Inc |
CANINE ERITHROPOIETINE GENE AND RECOMBINANT PROTEIN
|
US20050181482A1
(en)
*
|
2004-02-12 |
2005-08-18 |
Meade Harry M. |
Method for the production of an erythropoietin analog-human IgG fusion proteins in transgenic mammal milk
|
EP1088084B1
(en)
*
|
1998-06-15 |
2006-09-13 |
GTC Biotherapeutics, Inc. |
Erythropoietin analog-human serum albumin fusion protein
|
US6541033B1
(en)
|
1998-06-30 |
2003-04-01 |
Amgen Inc. |
Thermosensitive biodegradable hydrogels for sustained delivery of leptin
|
WO2000006205A1
(en)
*
|
1998-07-29 |
2000-02-10 |
Invitrogen Corporation |
Regulated expression of recombinant proteins using rna viruses
|
EP0984062A1
(en)
*
|
1998-09-04 |
2000-03-08 |
Cytos Biotechnology AG |
Production of human erythropoietin
|
US6420339B1
(en)
|
1998-10-14 |
2002-07-16 |
Amgen Inc. |
Site-directed dual pegylation of proteins for improved bioactivity and biocompatibility
|
US7304150B1
(en)
|
1998-10-23 |
2007-12-04 |
Amgen Inc. |
Methods and compositions for the prevention and treatment of anemia
|
US6660843B1
(en)
|
1998-10-23 |
2003-12-09 |
Amgen Inc. |
Modified peptides as therapeutic agents
|
BR9905867A
(pt)
*
|
1998-11-06 |
2001-01-23 |
Bio Sidus S A |
Linhagem celular produtora de eritropoietina humana recombinante e a eritropoietina humana recombinante produzida por esta célula
|
US6777205B1
(en)
|
1998-11-06 |
2004-08-17 |
Sterrenbeld Biotechnologie North America, Inc. |
Host cells expressing recombinant human erythropoietin
|
BR9917606A
(pt)
|
1998-11-06 |
2002-12-31 |
Bio Sidus S A |
Procedimento para a purificação de eritropoetina humana recombinante a partir de sobrenadantes de cultivo de células e eritropoetina humana recombinante obtida com tal procedimento
|
BR9905868A
(pt)
|
1998-11-06 |
2001-01-23 |
Bio Sidus S A |
Procedimento de cultivo massivo de células de mamìfero para a obtenção de eritropoetina humana, recombinante e a eritropoetina humana recombinante obtida com tal procedimento
|
DE19857609A1
(de)
|
1998-12-14 |
2000-06-15 |
Hannelore Ehrenreich |
Verwendung von Erythropoietin zur Behandlung von cerebralen Ischämien des Menschen
|
US6451346B1
(en)
*
|
1998-12-23 |
2002-09-17 |
Amgen Inc |
Biodegradable pH/thermosensitive hydrogels for sustained delivery of biologically active agents
|
US6245740B1
(en)
|
1998-12-23 |
2001-06-12 |
Amgen Inc. |
Polyol:oil suspensions for the sustained release of proteins
|
DE19905501B4
(de)
|
1999-02-10 |
2005-05-19 |
MediGene AG, Gesellschaft für molekularbiologische Kardiologie und Onkologie |
Verfahren zur Herstellung eines rekombinanten Adeno-assoziierten Virus, geeignete Mittel hierzu sowie Verwendung zur Herstellung eines Arzneimittels
|
US7345019B1
(en)
|
1999-04-13 |
2008-03-18 |
The Kenneth S. Warren Institute, Inc. |
Modulation of excitable tissue function by peripherally administered erythropoietin
|
US7410941B1
(en)
|
1999-04-13 |
2008-08-12 |
The Kenneth S. Warren Institute, Inc. |
Methods for treatment of neurodegenerative conditions by peripherally administered erythropoietin
|
US7604960B2
(en)
*
|
1999-04-15 |
2009-10-20 |
Crucell Holland B.V. |
Transient protein expression methods
|
US6855544B1
(en)
|
1999-04-15 |
2005-02-15 |
Crucell Holland B.V. |
Recombinant protein production in a human cell
|
US20050170463A1
(en)
*
|
1999-04-15 |
2005-08-04 |
Abraham Bout |
Recombinant protein production in permanent amniocytic cells that comprise nucleic acid encoding adenovirus E1A and E1B proteins
|
US20050164386A1
(en)
*
|
1999-04-15 |
2005-07-28 |
Uytdehaag Alphonsus G. |
Overexpression of enzymes involved in post-translational protein modifications in human cells
|
US8236561B2
(en)
*
|
1999-04-15 |
2012-08-07 |
Crucell Holland B.V. |
Efficient production of IgA in recombinant mammalian cells
|
US7297680B2
(en)
|
1999-04-15 |
2007-11-20 |
Crucell Holland B.V. |
Compositions of erythropoietin isoforms comprising Lewis-X structures and high sialic acid content
|
WO2003048348A2
(en)
*
|
2001-12-07 |
2003-06-12 |
Crucell Holland B.V. |
Production of viruses, viral isolates and vaccines
|
WO2000068376A1
(en)
*
|
1999-05-07 |
2000-11-16 |
Genentech, Inc. |
Novel chimpanzee erythropoietin (chepo) polypeptides and nucleic acids encoding the same
|
US6555343B1
(en)
|
1999-05-07 |
2003-04-29 |
Genentech Inc. |
Chimpanzee erythropoietin (CHEPO) polypeptides and nucleic acids encoding the same
|
US6831060B2
(en)
|
1999-05-07 |
2004-12-14 |
Genentech, Inc. |
Chimpanzee erythropoietin (CHEPO) polypeptides and nucleic acids encoding the same
|
AT409379B
(de)
|
1999-06-02 |
2002-07-25 |
Baxter Ag |
Medium zur protein- und serumfreien kultivierung von zellen
|
SK782002A3
(en)
|
1999-07-21 |
2003-08-05 |
Lexigen Pharm Corp |
FC fusion proteins for enhancing the immunogenicity of protein and peptide antigens
|
US7067110B1
(en)
|
1999-07-21 |
2006-06-27 |
Emd Lexigen Research Center Corp. |
Fc fusion proteins for enhancing the immunogenicity of protein and peptide antigens
|
US6737519B1
(en)
|
1999-07-30 |
2004-05-18 |
Genome Therapeutics Corporation |
Human genes relating to respiratory diseases and obesity
|
DK1200479T3
(da)
*
|
1999-08-09 |
2006-05-15 |
Emd Lexigen Res Ct Corp |
Multiple cytokin-antistof-komplekser
|
US8106098B2
(en)
*
|
1999-08-09 |
2012-01-31 |
The General Hospital Corporation |
Protein conjugates with a water-soluble biocompatible, biodegradable polymer
|
US20050202538A1
(en)
*
|
1999-11-12 |
2005-09-15 |
Merck Patent Gmbh |
Fc-erythropoietin fusion protein with improved pharmacokinetics
|
JP2003514552A
(ja)
|
1999-11-12 |
2003-04-22 |
メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフトング |
改善された性質を有するエリトロポエチンの形態
|
US6703480B1
(en)
|
1999-11-24 |
2004-03-09 |
Palani Balu |
Peptide dimers as agonists of the erythropoientin (EPO) receptor, and associated methods of synthesis and use
|
US7192759B1
(en)
*
|
1999-11-26 |
2007-03-20 |
Crucell Holland B.V. |
Production of vaccines
|
US7521220B2
(en)
*
|
1999-11-26 |
2009-04-21 |
Crucell Holland B.V. |
Production of vaccines
|
US7527961B2
(en)
*
|
1999-11-26 |
2009-05-05 |
Crucell Holland B.V. |
Production of vaccines
|
AU1647501A
(en)
|
1999-12-10 |
2001-06-18 |
Cytos Biotechnology Ag |
Replicon based activation of endogenous genes
|
CA2399832C
(en)
|
2000-02-11 |
2011-09-20 |
Stephen D. Gillies |
Enhancing the circulating half-life of antibody-based fusion proteins
|
EP2267026A1
(en)
|
2000-04-12 |
2010-12-29 |
Human Genome Sciences, Inc. |
Albumin fusion proteins
|
US20050100991A1
(en)
*
|
2001-04-12 |
2005-05-12 |
Human Genome Sciences, Inc. |
Albumin fusion proteins
|
IES20010462A2
(en)
*
|
2000-05-12 |
2001-11-14 |
Cyril John Higgins |
Use of the world wide web
|
DK1294401T3
(da)
*
|
2000-06-29 |
2007-10-08 |
Merck Patent Gmbh |
Forbedring af antistof/cytokin-fusionsproteinmedierede immunresponser ved kombineret behandling med immuncytokin-optagelsesforberende midler
|
NZ523831A
(en)
*
|
2000-07-13 |
2005-10-28 |
Invitrogen Corp |
Methods and compositions for rapid protein and peptide extraction and isolation using a lysis matrix
|
US7855229B2
(en)
*
|
2000-08-24 |
2010-12-21 |
University Of Tennessee Research Foundation |
Treating wasting disorders with selective androgen receptor modulators
|
US7622503B2
(en)
|
2000-08-24 |
2009-11-24 |
University Of Tennessee Research Foundation |
Selective androgen receptor modulators and methods of use thereof
|
US7645898B2
(en)
*
|
2000-08-24 |
2010-01-12 |
University Of Tennessee Research Foundation |
Selective androgen receptor modulators and method of use thereof
|
US7919647B2
(en)
|
2000-08-24 |
2011-04-05 |
University Of Tennessee Research Foundation |
Selective androgen receptor modulators and methods of use thereof
|
WO2002024899A2
(en)
|
2000-09-25 |
2002-03-28 |
Valentis, Inc. |
Improved system for regulation of transgene expression
|
US7087224B2
(en)
|
2000-10-31 |
2006-08-08 |
Amgen Inc. |
Method of treating anemia by administering IL-1ra
|
MXPA03005406A
(es)
|
2000-12-20 |
2003-09-25 |
Hoffmann La Roche |
Conjugados de eritropoyetina.
|
US6531121B2
(en)
*
|
2000-12-29 |
2003-03-11 |
The Kenneth S. Warren Institute, Inc. |
Protection and enhancement of erythropoietin-responsive cells, tissues and organs
|
US20030072737A1
(en)
*
|
2000-12-29 |
2003-04-17 |
Michael Brines |
Tissue protective cytokines for the protection, restoration, and enhancement of responsive cells, tissues and organs
|
US7767643B2
(en)
*
|
2000-12-29 |
2010-08-03 |
The Kenneth S. Warren Institute, Inc. |
Protection, restoration, and enhancement of erythropoietin-responsive cells, tissues and organs
|
KR100399337B1
(ko)
*
|
2001-02-07 |
2003-09-26 |
드림바이오젠 주식회사 |
단백질의 무세포 번역후수식법
|
AU2002248571B2
(en)
*
|
2001-03-07 |
2007-01-18 |
Merck Patent Gmbh |
Expression technology for proteins containing a hybrid isotype antibody moiety
|
DE10112825A1
(de)
|
2001-03-16 |
2002-10-02 |
Fresenius Kabi De Gmbh |
HESylierung von Wirkstoffen in wässriger Lösung
|
WO2002079415A2
(en)
|
2001-03-30 |
2002-10-10 |
Lexigen Pharmaceuticals Corp. |
Reducing the immunogenicity of fusion proteins
|
BR0209177A
(pt)
|
2001-05-03 |
2004-10-05 |
Merck Patent Gmbh |
Anticorpo especìfico a tumor recombinante e uso do mesmo
|
CA2446739A1
(en)
*
|
2001-05-25 |
2002-12-05 |
Human Genome Sciences, Inc. |
Chemokine beta-1 fusion proteins
|
CA2456821A1
(en)
*
|
2001-08-02 |
2003-02-13 |
Trinity Biomedical Technology Corporation |
Human zona pellucida proteins and methods of their use in diagnosing male infertility
|
US20030104996A1
(en)
*
|
2001-08-30 |
2003-06-05 |
Tiansheng Li |
L-methionine as a stabilizer for NESP/EPO in HSA-free formulations
|
EP1423509A2
(en)
*
|
2001-08-30 |
2004-06-02 |
Stem Cell Therapeutics Inc. |
Differentiation of neural stem cells and therapeutic use thereof
|
EP1430114B1
(en)
*
|
2001-09-14 |
2012-01-18 |
Stem Cell Therapeutics Inc. |
Prolactin induced increase in neural stem cell numbers and therapeutical use thereof
|
AR036402A1
(es)
*
|
2001-09-18 |
2004-09-08 |
Stem Cell Therapeutics Inc |
Efecto de la hormona de crecimiento y de igf-1 sobre celulas madre neuronales.
|
KR20040065231A
(ko)
*
|
2001-11-28 |
2004-07-21 |
산도즈 게엠베하 |
세포 배양 방법
|
EP2354791A1
(en)
*
|
2001-12-04 |
2011-08-10 |
Merck Patent GmbH |
Immunocytokines with modulated selectivity
|
US8853266B2
(en)
*
|
2001-12-06 |
2014-10-07 |
University Of Tennessee Research Foundation |
Selective androgen receptor modulators for treating diabetes
|
US20070161608A1
(en)
*
|
2001-12-06 |
2007-07-12 |
Dalton James T |
Selective androgen receptor modulators for treating muscle wasting
|
PT1463751E
(pt)
|
2001-12-21 |
2013-08-26 |
Human Genome Sciences Inc |
Proteínas de fusão de albumina
|
AU2002364587A1
(en)
*
|
2001-12-21 |
2003-07-30 |
Human Genome Sciences, Inc. |
Albumin fusion proteins
|
WO2005003296A2
(en)
|
2003-01-22 |
2005-01-13 |
Human Genome Sciences, Inc. |
Albumin fusion proteins
|
WO2003054172A2
(en)
|
2002-01-17 |
2003-07-03 |
Lonza Biologics Plc. |
Glutamine-auxothrophic human cells capable of producing proteins and capable of growing in a glutamine-free medium
|
DE10209822A1
(de)
|
2002-03-06 |
2003-09-25 |
Biotechnologie Ges Mittelhesse |
Kopplung niedermolekularer Substanzen an ein modifiziertes Polysaccharid
|
DE10209821A1
(de)
|
2002-03-06 |
2003-09-25 |
Biotechnologie Ges Mittelhesse |
Kopplung von Proteinen an ein modifiziertes Polysaccharid
|
US20030191056A1
(en)
|
2002-04-04 |
2003-10-09 |
Kenneth Walker |
Use of transthyretin peptide/protein fusions to increase the serum half-life of pharmacologically active peptides/proteins
|
US20050256035A1
(en)
*
|
2002-05-13 |
2005-11-17 |
Irving Boime |
Ctp-extended erythropoietin
|
AU2003251770B9
(en)
*
|
2002-07-01 |
2009-06-04 |
H. Lundbeck A/S |
Recombinant tissue protective cytokines and encoding nucleic acids thereof for protection, restoration, and enhancement of responsive cells, tissues, and organs
|
JP2005532057A
(ja)
|
2002-07-09 |
2005-10-27 |
バクスター・インターナショナル・インコーポレイテッド |
細胞を培養するための動物性タンパク質非含有培地
|
DE10234192B4
(de)
|
2002-07-26 |
2009-11-26 |
Epoplus Gmbh Co.Kg |
Verwendung von Erythropoetin
|
AU2003250705A1
(en)
*
|
2002-07-31 |
2004-02-16 |
Stem Cell Therapeutics Inc. |
Method of enhancing neural stem cell proliferation, differentiation, and survival using pituitary adenylate cyclase activating polypeptide (pacap)
|
WO2004020576A2
(en)
*
|
2002-08-31 |
2004-03-11 |
Cj Corp. |
Glycosylated human granulocyte colony-stimulating factor (g-csf) isoform
|
DE60332358D1
(de)
*
|
2002-09-09 |
2010-06-10 |
Hanall Pharmaceutical Co Ltd |
Protease-resistente modifizierte interferon alpha polypeptide
|
EP1681303B1
(en)
|
2002-09-11 |
2013-09-04 |
Fresenius Kabi Deutschland GmbH |
HASylated polypeptides, especially HASylated erythropoietin
|
KR101045422B1
(ko)
|
2002-09-11 |
2011-06-30 |
프레제니우스 카비 도이치란트 게엠베하 |
하이드록시알킬 전분 유도체의 제조 방법
|
DE20321793U1
(de)
|
2002-09-11 |
2010-06-02 |
Fresenius Kabi Deutschland Gmbh |
Hydroxyalkylstärke-Derivate
|
ATE409048T1
(de)
|
2002-10-08 |
2008-10-15 |
Fresenius Kabi De Gmbh |
Pharmazeutisch aktive oligosaccharid-conjugate
|
BRPI0317376B8
(pt)
*
|
2002-12-17 |
2021-05-25 |
Merck Patent Gmbh |
proteína de fusão de anticorpo-il2 designada como hu14.18-il2, usos da mesma, vetor e composição farmacêutica
|
CA2514941A1
(en)
*
|
2003-02-03 |
2004-08-19 |
Immuno Japan Inc. |
High-expression vector for animal cells
|
US8084424B2
(en)
*
|
2003-04-09 |
2011-12-27 |
University Of Utah Research Foundation |
Compositions and methods related to erythropoietin
|
US7459152B2
(en)
*
|
2003-04-23 |
2008-12-02 |
Rush University Medical Center |
Erythropoietin administration to improve graft survival
|
WO2004099396A1
(en)
|
2003-05-09 |
2004-11-18 |
Crucell Holland B.V. |
Cultures of e1-immortalized cells and processes for culturing the same to increase product yields therefrom
|
MXPA05012314A
(es)
*
|
2003-05-12 |
2006-04-18 |
Affymax Inc |
Radical separador para peptido modificado con polietilenglicol.
|
WO2004101600A2
(en)
*
|
2003-05-12 |
2004-11-25 |
Affymax, Inc. |
Novel poly(ethylene glycol) modified compounds and uses thereof
|
ES2395413T3
(es)
*
|
2003-05-12 |
2013-02-12 |
Affymax, Inc. |
Péptidos que se unen al receptor de eritropoyetina
|
ES2323465T3
(es)
*
|
2003-05-12 |
2009-07-16 |
Affymax, Inc. |
Peptidos novedosos que se unen al receptor de la eritropoyetina.
|
EP1626992B1
(en)
*
|
2003-05-23 |
2010-06-02 |
Crucell Holland B.V. |
Production of recombinant igm in per.c6 cells
|
EP1641486B1
(en)
|
2003-06-10 |
2012-04-18 |
LG Life Sciences Ltd. |
Stable, aqueous solution of human erythropoietin, not containing serum albumin
|
EP2311994A1
(en)
*
|
2003-08-01 |
2011-04-20 |
Life Technologies Corporation |
Compositions and methods for preparing short RNA molecules and other nucleic acids
|
WO2005014655A2
(en)
|
2003-08-08 |
2005-02-17 |
Fresenius Kabi Deutschland Gmbh |
Conjugates of hydroxyalkyl starch and a protein
|
CN1897959A
(zh)
|
2003-09-29 |
2007-01-17 |
沃伦药品公司 |
用于治疗和预防脓毒病和粘连形成的组织保护细胞因子
|
BRPI0418326A
(pt)
|
2003-12-30 |
2007-05-02 |
Bionethos Holding Gmbh |
método de regeneração de tecidos
|
JP2007517042A
(ja)
|
2003-12-30 |
2007-06-28 |
デュレクト コーポレーション |
活性物質、好ましくはgnrhの制御放出のための、好ましくはpegおよびplgの混合物を含有するポリマーインプラント
|
AU2004309063B2
(en)
*
|
2003-12-31 |
2010-10-28 |
Merck Patent Gmbh |
Fc-erythropoietin fusion protein with improved pharmacokinetics
|
DE102004063927A1
(de)
|
2004-01-23 |
2005-12-15 |
Epoplus Gmbh Co.Kg |
Einsatz von niedrig dosiertem Erythropoietin zur Stimulation endothelialer Vorläuferzellen sowie zur Organregeneration und Progressionsverlangsamung von Endorganschäden
|
CA2556266A1
(en)
*
|
2004-02-13 |
2005-08-25 |
Stem Cell Therapeutics Corp. |
Use of luteinizing hormone (lh), and chorionic gonadotropin (hcg) for proliferation of neural stem cells and neurogenesis
|
US7255288B2
(en)
*
|
2004-03-08 |
2007-08-14 |
Wan Shan Chan |
Aroma therapy for fountain
|
ES2390885T3
(es)
|
2004-03-11 |
2012-11-19 |
Fresenius Kabi Deutschland Gmbh |
Conjugados de hidroxialquilalmidón y una proteína
|
WO2005092928A1
(en)
|
2004-03-11 |
2005-10-06 |
Fresenius Kabi Deutschland Gmbh |
Conjugates of hydroxyalkyl starch and a protein, prepared by reductive amination
|
US7588745B2
(en)
*
|
2004-04-13 |
2009-09-15 |
Si Options, Llc |
Silicon-containing products
|
US9884038B2
(en)
|
2004-06-07 |
2018-02-06 |
University Of Tennessee Research Foundation |
Selective androgen receptor modulator and methods of use thereof
|
US20110237664A1
(en)
*
|
2004-06-07 |
2011-09-29 |
Dalton James T |
Selective androgen receptor modulators for treating diabetes
|
US9889110B2
(en)
|
2004-06-07 |
2018-02-13 |
University Of Tennessee Research Foundation |
Selective androgen receptor modulator for treating hormone-related conditions
|
US20060094104A1
(en)
|
2004-10-29 |
2006-05-04 |
Leopold Grillberger |
Animal protein-free media for cultivation of cells
|
JP2008519858A
(ja)
*
|
2004-11-11 |
2008-06-12 |
アフィーマックス・インコーポレイテッド |
エリスロポエチンレセプターに結合する新規ペプチド
|
WO2006062685A2
(en)
*
|
2004-11-11 |
2006-06-15 |
Affymax, Inc. |
Novel peptides that bind to the erythropoietin receptor
|
WO2006061853A2
(en)
*
|
2004-12-10 |
2006-06-15 |
Serum Institute Of India Limited |
Novel erythropoietic compounds and a process for producing erythropoietic compounds
|
EP1848461A2
(en)
*
|
2005-02-16 |
2007-10-31 |
Nektar Therapeutics Al, Corporation |
Conjugates of an epo moiety and a polymer
|
US8324159B2
(en)
*
|
2005-06-03 |
2012-12-04 |
Affymax, Inc. |
Erythropoietin receptor peptide formulations and uses
|
US7919461B2
(en)
|
2005-06-03 |
2011-04-05 |
Affymax, Inc. |
Erythropoietin receptor peptide formulations and uses
|
US7550433B2
(en)
*
|
2005-06-03 |
2009-06-23 |
Affymax, Inc. |
Erythropoietin receptor peptide formulations and uses
|
EP1931199A4
(en)
|
2005-08-31 |
2009-07-29 |
Univ Tennessee Res Foundation |
TREATMENT OF RENAL DISEASE, BURNS, INJURIES OR SPINAL CORD INJURY USING ANDROGEN RECEPTOR SELECTIVE MODULATORS
|
EP1762250A1
(en)
|
2005-09-12 |
2007-03-14 |
Fresenius Kabi Deutschland GmbH |
Conjugates of hydroxyalkyl starch and an active substance, prepared by chemical ligation via thiazolidine
|
US7534765B2
(en)
*
|
2005-09-27 |
2009-05-19 |
Stem Cell Therapeutics Corp. |
Pregnancy-induced oligodendrocyte precursor cell proliferation regulated by prolactin
|
US9388382B2
(en)
*
|
2005-10-05 |
2016-07-12 |
The Board Of Trustees Of The University Of Illinois |
Isolation of CD14 negative, CD45 positive and CD117 positive embryonic-like stem cells free of monocytes from human umbilical cord blood mononuclear cells
|
WO2008048671A1
(en)
*
|
2006-10-18 |
2008-04-24 |
University Of Illinois |
Embryonic-like stem cells derived from adult human peripheral blood and methods of use
|
CA2621705A1
(en)
*
|
2005-11-24 |
2007-05-31 |
Laboratoires Serono S.A. |
Erythropoietin polypeptides and uses thereof
|
AU2006324163B2
(en)
|
2005-12-08 |
2013-05-02 |
Amgen Inc. |
Improved production of glycoproteins using manganese
|
EP2522717B1
(en)
|
2006-01-04 |
2014-04-02 |
Baxter International Inc |
Oligopeptide-free cell culture media
|
US7625564B2
(en)
|
2006-01-27 |
2009-12-01 |
Novagen Holding Corporation |
Recombinant human EPO-Fc fusion proteins with prolonged half-life and enhanced erythropoietic activity in vivo
|
DE102006004008A1
(de)
|
2006-01-27 |
2007-08-02 |
Hannelore Prof. Dr. Dr. Ehrenreich |
Verfahren zur Behandlung und/oder Prophylaxe von Multipler Sklerose, sowie Verwendung von Erythropoietin zur Herstellung eines Arzneimittels zur intermittierenden Behandlung und/oder intermittierenden Prophylaxe von Multipler Sklerose
|
KR20080106976A
(ko)
*
|
2006-03-17 |
2008-12-09 |
스템 셀 테라퓨틱스 코포레이션 |
신경 줄기 세포 증식제 및 신경 줄기 세포 분화제의 연속 투여 방법
|
WO2007108505A1
(ja)
|
2006-03-22 |
2007-09-27 |
Chugai Seiyaku Kabushiki Kaisha |
エリスロポエチン溶液製剤
|
CN101062407A
(zh)
|
2006-04-29 |
2007-10-31 |
中国科学院上海生命科学研究院 |
促红细胞生成素在预防或治疗视网膜损伤中的用途
|
CA2658394C
(en)
|
2006-07-12 |
2016-08-16 |
University Of Tennessee Research Foundation |
Substituted acylanilides and methods of use thereof
|
EP2054074B8
(en)
|
2006-08-04 |
2014-11-12 |
Prolong Pharmaceuticals, LLC |
Modified erythropoietin
|
WO2008023725A1
(fr)
|
2006-08-22 |
2008-02-28 |
Chugai Seiyaku Kabushiki Kaisha |
Agent préventif et/ou thérapeutique pour une neuropathie périphérique
|
DK2054049T3
(en)
|
2006-08-24 |
2016-08-01 |
Univ Tennessee Res Found |
SUBSTITUTED ACYLANILIDES AND PROCEDURES FOR USING THEREOF
|
CN102886052B
(zh)
|
2006-09-14 |
2014-07-30 |
迈德詹尼克斯医疗以色列有限公司 |
长效药物制剂
|
US8454948B2
(en)
|
2006-09-14 |
2013-06-04 |
Medgenics Medical Israel Ltd. |
Long lasting drug formulations
|
JP2010510794A
(ja)
|
2006-11-28 |
2010-04-08 |
ハナル ファーマシューティカル カンパニー リミテッド |
修飾型エリスロポエチンポリペプチド及びこの治療用用途
|
EP2089424B1
(en)
*
|
2006-12-06 |
2015-07-01 |
JCR PHARMACEUTICALS Co., LTD. |
Method for production of human erythropoietin
|
EP2121017A2
(en)
*
|
2006-12-19 |
2009-11-25 |
Nokad |
Method for inhibiting the expression of endogenous erythropoietin (epo)
|
TW200900420A
(en)
*
|
2007-02-02 |
2009-01-01 |
Amgen Inc |
Hepcidin, hepcidin antagonists and methods of use
|
AR065613A1
(es)
|
2007-03-09 |
2009-06-17 |
Chugai Pharmaceutical Co Ltd |
Agentes de proteccion para organos transplantados
|
US20080260820A1
(en)
*
|
2007-04-19 |
2008-10-23 |
Gilles Borrelly |
Oral dosage formulations of protease-resistant polypeptides
|
EP2167115A2
(en)
|
2007-06-15 |
2010-03-31 |
University Of Zurich |
Treatment for alzheimer's disease
|
WO2009010107A1
(en)
|
2007-07-19 |
2009-01-22 |
Hannelore Ehrenreich |
Use of epo receptor activation or stimulation for the improvement of the edss score in patients with multiple sclerosis
|
BRPI0814465B1
(pt)
|
2007-07-26 |
2021-11-23 |
Novagen Holding Corporation |
Proteína de fusão, dímero, método para produzir uma proteína de fusão, linhagem de célula, usos de uma proteína de fusão e de uma composição farmacêutica e composição farmacêutica
|
US7968603B2
(en)
|
2007-09-11 |
2011-06-28 |
University Of Tennessee Research Foundation |
Solid forms of selective androgen receptor modulators
|
CA2701032C
(en)
|
2007-09-27 |
2021-01-26 |
Amgen Inc. |
Pharmaceutical formulations
|
EP3381445B1
(en)
|
2007-11-15 |
2023-10-25 |
Amgen Inc. |
Aqueous formulation of antibody stablised by antioxidants for parenteral administration
|
EP2070950A1
(en)
|
2007-12-14 |
2009-06-17 |
Fresenius Kabi Deutschland GmbH |
Hydroxyalkyl starch derivatives and process for their preparation
|
US9175078B2
(en)
|
2008-01-25 |
2015-11-03 |
Amgen Inc. |
Ferroportin antibodies and methods of use
|
EP3103880A1
(en)
|
2008-02-08 |
2016-12-14 |
Ambrx, Inc. |
Modified leptin polypeptides and their uses
|
EP2095829A1
(en)
|
2008-02-27 |
2009-09-02 |
LEK Pharmaceuticals D.D. |
Selenium containing modifying agents and conjugates
|
AU2009218069B2
(en)
|
2008-02-27 |
2014-05-01 |
Fuso Pharmaceutical Industries, Ltd. |
Expression vector for mass production of foreign gene-derived protein using animal cell and use thereof
|
CA2722600C
(en)
|
2008-05-01 |
2014-01-21 |
Amgen Inc. |
Anti-hepcidin antibodies and methods of use
|
DE102008002209A1
(de)
|
2008-06-04 |
2009-12-10 |
Evonik Degussa Gmbh |
Verfahren zur Aufreinigung von Erythropoietin
|
DE102008002210A1
(de)
|
2008-06-04 |
2009-12-10 |
Evonik Degussa Gmbh |
Verfahren zur fermentativen Herstellung von Erythropoietin
|
US8003689B2
(en)
*
|
2008-06-20 |
2011-08-23 |
Gtx, Inc. |
Metabolites of selective androgen receptor modulators and methods of use thereof
|
ES2435272T3
(es)
|
2008-09-23 |
2013-12-17 |
F. Hoffmann-La Roche Ag |
Purificación de la eritropoyetina
|
EP3216800A1
(en)
*
|
2008-09-26 |
2017-09-13 |
Ambrx, Inc. |
Modified animal erythropoietin polypeptides and their uses
|
CA2742871C
(en)
|
2008-11-13 |
2018-10-23 |
Herb Lin |
Methods and compositions for regulating iron homeostasis by modulation of bmp-6
|
DE102008054716A1
(de)
|
2008-12-16 |
2010-06-17 |
Evonik Degussa Gmbh |
Inprozesskontrolle in einem Verfahren zur Herstellung von EPO
|
WO2010074080A1
(ja)
|
2008-12-22 |
2010-07-01 |
国立大学法人北海道大学 |
動物細胞を用いて外来遺伝子由来タンパク質を大量に生産するための発現ベクター、およびその利用
|
US20100272816A1
(en)
|
2009-04-27 |
2010-10-28 |
Wolfgang Rudinger |
Microcapsules comprising liver cells and erythropoietin, methods for preparing said microcapsules and methods for treating a patient comprising applying said microcapsules to the patient
|
JP5879256B2
(ja)
|
2009-05-02 |
2016-03-08 |
ジェンザイム・コーポレーション |
神経変性障害のための遺伝子治療
|
JP5728016B2
(ja)
|
2009-09-23 |
2015-06-03 |
ラチオファーマ ゲーエムベーハー |
組換えヒトエリスロポエチン(epo)を精製するためのプロセス、このようにして精製されたepoおよびこれを含む医薬組成物
|
AU2010310457B2
(en)
|
2009-10-23 |
2015-07-02 |
Amgen Inc. |
Vial adapter and system
|
RS54291B2
(sr)
|
2010-06-07 |
2023-12-29 |
Amgen Inc |
Uređaj za isporuku lekova
|
AU2011268458B2
(en)
|
2010-06-15 |
2014-06-12 |
Medgenics Medical Israel Ltd. |
Long lasting drug formulations
|
PT2621519T
(pt)
|
2010-09-28 |
2017-10-04 |
Aegerion Pharmaceuticals Inc |
Polipéptido de fusão de leptina-abd com duração de ação melhorada
|
MX341790B
(es)
|
2011-03-31 |
2016-09-02 |
Amgen Inc |
Adaptador de viales y sistema.
|
PL2699293T3
(pl)
|
2011-04-20 |
2019-08-30 |
Amgen Inc. |
Urządzenie do wstrzykiwania automatycznego
|
DK3045189T3
(en)
|
2011-10-14 |
2018-06-18 |
Amgen Inc |
Injector and mounting method
|
KR101443257B1
(ko)
|
2011-10-18 |
2014-09-19 |
주식회사 종근당 |
낮은 등전점을 갖는 에리스로포이에틴 유사체의 정제방법
|
EP2771300B1
(en)
|
2011-10-25 |
2017-12-20 |
Corning Incorporated |
Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
|
US10350139B2
(en)
|
2011-10-25 |
2019-07-16 |
Corning Incorporated |
Pharmaceutical glass packaging assuring pharmaceutical sterility
|
US10314807B2
(en)
|
2012-07-13 |
2019-06-11 |
Gtx, Inc. |
Method of treating HER2-positive breast cancers with selective androgen receptor modulators (SARMS)
|
US10987334B2
(en)
|
2012-07-13 |
2021-04-27 |
University Of Tennessee Research Foundation |
Method of treating ER mutant expressing breast cancers with selective androgen receptor modulators (SARMs)
|
US9969683B2
(en)
|
2012-07-13 |
2018-05-15 |
Gtx, Inc. |
Method of treating estrogen receptor (ER)-positive breast cancers with selective androgen receptor modulator (SARMS)
|
US9744149B2
(en)
|
2012-07-13 |
2017-08-29 |
Gtx, Inc. |
Method of treating androgen receptor (AR)-positive breast cancers with selective androgen receptor modulator (SARMs)
|
KR102238970B1
(ko)
|
2012-07-13 |
2021-04-09 |
지티엑스, 인코포레이티드 |
선택적 안드로겐 수용체 조절자(sarms)를 이용한 안드로겐 수용체(ar) 양성 유방암의 치료 방법
|
US9622992B2
(en)
|
2012-07-13 |
2017-04-18 |
Gtx, Inc. |
Method of treating androgen receptor (AR)-positive breast cancers with selective androgen receptor modulator (SARMs)
|
US10258596B2
(en)
|
2012-07-13 |
2019-04-16 |
Gtx, Inc. |
Method of treating HER2-positive breast cancers with selective androgen receptor modulators (SARMS)
|
US9650411B2
(en)
|
2012-08-07 |
2017-05-16 |
Kyowa Hakko Kirin Co., Ltd. |
Method of purifying protein
|
WO2014062535A1
(en)
|
2012-10-15 |
2014-04-24 |
Bristol-Myers Squibb Company |
Mammalian cell culture processes for protein production
|
ES2780395T3
(es)
|
2012-11-21 |
2020-08-25 |
Amgen Inc |
Dispositivo de administración de fármacos
|
EA201591281A1
(ru)
|
2013-03-14 |
2016-02-29 |
Шир Хьюман Дженетик Терапис, Инк. |
Рибонуклеиновые кислоты с 4'-тиомодифицированными нуклеотидами и связанные с ними способы
|
KR102218494B1
(ko)
|
2013-03-15 |
2021-02-19 |
인트린식 라이프사이언시스, 엘엘씨 |
항-헵시딘 항체 및 그의 용도
|
WO2014138921A1
(en)
|
2013-03-15 |
2014-09-18 |
Apotex Inc. |
Enhanced liquid formulation stability of erythropoietin alpha through purification processing
|
JP6768501B2
(ja)
|
2013-03-15 |
2020-10-14 |
アムゲン・インコーポレーテッド |
薬物カセット、自動注入機、および自動注入機システム
|
US10092703B2
(en)
|
2013-03-15 |
2018-10-09 |
Amgen Inc. |
Drug cassette, autoinjector, and autoinjector system
|
BR112015024282B1
(pt)
|
2013-03-22 |
2022-05-17 |
Amgen Inc |
Injetor e método de montagem do injetor
|
US9713572B2
(en)
|
2013-04-24 |
2017-07-25 |
Corning Incorporated |
Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
|
US9707154B2
(en)
|
2013-04-24 |
2017-07-18 |
Corning Incorporated |
Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
|
US9707153B2
(en)
|
2013-04-24 |
2017-07-18 |
Corning Incorporated |
Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
|
US9603775B2
(en)
|
2013-04-24 |
2017-03-28 |
Corning Incorporated |
Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
|
US9700485B2
(en)
|
2013-04-24 |
2017-07-11 |
Corning Incorporated |
Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
|
US9717648B2
(en)
|
2013-04-24 |
2017-08-01 |
Corning Incorporated |
Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
|
US9700486B2
(en)
|
2013-04-24 |
2017-07-11 |
Corning Incorporated |
Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
|
US9839579B2
(en)
|
2013-04-24 |
2017-12-12 |
Corning Incorporated |
Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
|
US9717649B2
(en)
|
2013-04-24 |
2017-08-01 |
Corning Incorporated |
Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
|
US9707155B2
(en)
|
2013-04-24 |
2017-07-18 |
Corning Incorporated |
Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
|
US9849066B2
(en)
|
2013-04-24 |
2017-12-26 |
Corning Incorporated |
Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
|
BR112016002622B1
(pt)
|
2013-08-20 |
2023-04-11 |
Lek Pharmaceuticals D.D |
Meio de cultura celular e uso de selênio
|
CN105873626A
(zh)
|
2013-10-24 |
2016-08-17 |
美国安进公司 |
注射器和组装方法
|
US10758683B2
(en)
|
2013-10-24 |
2020-09-01 |
Amgen Inc. |
Drug delivery system with temperature-sensitive control
|
TW201522629A
(zh)
|
2013-10-24 |
2015-06-16 |
Medgenics Medical Israel Ltd |
提供治療多肽之持續遞送的微器官及其使用方法
|
US10994112B2
(en)
|
2014-02-05 |
2021-05-04 |
Amgen Inc. |
Drug delivery system with electromagnetic field generator
|
JP6640113B2
(ja)
|
2014-05-07 |
2020-02-05 |
アムジエン・インコーポレーテツド |
衝撃低減要素を有する自動注入器
|
WO2015181676A1
(en)
|
2014-05-30 |
2015-12-03 |
Pfizer Inc. |
Carbonitrile derivatives as selective androgen receptor modulators
|
CA2949846C
(en)
|
2014-06-03 |
2023-09-05 |
Amgen Inc. |
Devices and methods for assisting a user of a drug delivery device
|
EP3197915A4
(en)
|
2014-09-22 |
2018-12-19 |
Intrinsic Lifesciences LLC |
Humanized anti-hepcidin antibodies and uses thereof
|
MX2021014323A
(es)
|
2014-10-14 |
2023-02-02 |
Amgen Inc |
Dispositivo de inyección de fármaco con indicadores visuales y audibles.
|
US11357916B2
(en)
|
2014-12-19 |
2022-06-14 |
Amgen Inc. |
Drug delivery device with live button or user interface field
|
WO2016100781A1
(en)
|
2014-12-19 |
2016-06-23 |
Amgen Inc. |
Drug delivery device with proximity sensor
|
CA2976935C
(en)
|
2015-02-17 |
2020-03-10 |
Amgen Inc. |
Drug delivery device with vacuum assisted securement and/or feedback
|
US11806509B2
(en)
|
2015-02-27 |
2023-11-07 |
Amgen Inc. |
Drug delivery device having a needle guard mechanism with a turnable threshold of resistance to needle guard movement
|
WO2017039786A1
(en)
|
2015-09-02 |
2017-03-09 |
Amgen Inc. |
Syringe assembly adapter for a syringe
|
WO2017068051A1
(en)
|
2015-10-21 |
2017-04-27 |
Lek Pharmaceuticals D.D. |
Peg-based dendron and process for producing the same
|
JP7082568B2
(ja)
|
2015-12-09 |
2022-06-08 |
アムジエン・インコーポレーテツド |
信号伝達キャップ付き自動注射器
|
WO2017120178A1
(en)
|
2016-01-06 |
2017-07-13 |
Amgen Inc. |
Auto-injector with signaling electronics
|
WO2017160799A1
(en)
|
2016-03-15 |
2017-09-21 |
Amgen Inc. |
Reducing probability of glass breakage in drug delivery devices
|
WO2017189089A1
(en)
|
2016-04-29 |
2017-11-02 |
Amgen Inc. |
Drug delivery device with messaging label
|
US11389588B2
(en)
|
2016-05-02 |
2022-07-19 |
Amgen Inc. |
Syringe adapter and guide for filling an on-body injector
|
JP7309363B2
(ja)
|
2016-05-13 |
2023-07-18 |
アムジエン・インコーポレーテツド |
バイアル・スリーブ組立体
|
WO2017200989A1
(en)
|
2016-05-16 |
2017-11-23 |
Amgen Inc. |
Data encryption in medical devices with limited computational capability
|
EP3465124A1
(en)
|
2016-06-03 |
2019-04-10 |
Amgen Inc. |
Impact testing apparatuses and methods for drug delivery devices
|
US11285266B2
(en)
|
2016-07-01 |
2022-03-29 |
Amgen Inc. |
Drug delivery device having minimized risk of component fracture upon impact events
|
WO2018034784A1
(en)
|
2016-08-17 |
2018-02-22 |
Amgen Inc. |
Drug delivery device with placement detection
|
WO2018081234A1
(en)
|
2016-10-25 |
2018-05-03 |
Amgen Inc. |
On-body injector
|
JP2020503976A
(ja)
|
2017-01-17 |
2020-02-06 |
アムジエン・インコーポレーテツド |
注入デバイスならびに関連する使用および組立方法
|
JP7280189B2
(ja)
|
2017-02-17 |
2023-05-23 |
アムジエン・インコーポレーテツド |
薬物送達装置用の挿入機構
|
WO2018151890A1
(en)
|
2017-02-17 |
2018-08-23 |
Amgen Inc. |
Drug delivery device with sterile fluid flowpath and related method of assembly
|
CA3050927A1
(en)
|
2017-03-06 |
2018-09-13 |
Brian Stonecipher |
Drug delivery device with activation prevention feature
|
US11571511B2
(en)
|
2017-03-07 |
2023-02-07 |
Amgen Inc. |
Insertion mechanism and method of inserting a needle of a drug delivery device
|
WO2018165499A1
(en)
|
2017-03-09 |
2018-09-13 |
Amgen Inc. |
Insertion mechanism for drug delivery device
|
EP3570871B1
(en)
|
2017-03-20 |
2020-11-18 |
H. Hoffnabb-La Roche Ag |
Method for in vitro glycoengineering of an erythropoiesis stimulating protein
|
CA3052676A1
(en)
|
2017-03-28 |
2018-10-04 |
Amgen Inc. |
Plunger rod and syringe assembly system and method
|
AU2018280054B2
(en)
|
2017-06-08 |
2023-07-13 |
Amgen Inc. |
Syringe assembly for a drug delivery device and method of assembly
|
CN110709121B
(zh)
|
2017-06-08 |
2022-06-24 |
安进公司 |
扭矩驱动式药物递送装置
|
KR102268647B1
(ko)
|
2017-06-12 |
2021-06-23 |
한국코러스 주식회사 |
안정성이 향상된 에리스로포이에틴 조성물 및 이의 제조방법
|
MA49447A
(fr)
|
2017-06-22 |
2020-04-29 |
Amgen Inc |
Réduction des impacts/chocs d'activation d'un dispositif
|
EP3641861A1
(en)
|
2017-06-23 |
2020-04-29 |
Amgen Inc. |
Electronic drug delivery device comprising a cap activated by a switch assembly
|
WO2019014014A1
(en)
|
2017-07-14 |
2019-01-17 |
Amgen Inc. |
NEEDLE INSERTION-RETRACTING SYSTEM HAVING DOUBLE TORSION SPRING SYSTEM
|
MA49626A
(fr)
|
2017-07-21 |
2020-05-27 |
Amgen Inc |
Élément d'étanchéité perméable aux gaz pour récipient à médicament et procédés d'assemblage
|
MA49676A
(fr)
|
2017-07-25 |
2020-06-03 |
Amgen Inc |
Dispositif d'administration de médicament doté d'un système d'accès à un récipient et procédé d'assemblage associé
|
JP2020528296A
(ja)
|
2017-07-25 |
2020-09-24 |
アムジエン・インコーポレーテツド |
ギヤモジュールを有する薬物送達デバイス及び関連する組立方法
|
EP3664863A2
(en)
|
2017-08-09 |
2020-06-17 |
Amgen Inc. |
Hydraulic-pneumatic pressurized chamber drug delivery system
|
EP3668567A1
(en)
|
2017-08-18 |
2020-06-24 |
Amgen Inc. |
Wearable injector with sterile adhesive patch
|
US11103636B2
(en)
|
2017-08-22 |
2021-08-31 |
Amgen Inc. |
Needle insertion mechanism for drug delivery device
|
WO2019070472A1
(en)
|
2017-10-04 |
2019-04-11 |
Amgen Inc. |
FLOW ADAPTER FOR MEDICATION DELIVERY DEVICE
|
IL272636B1
(en)
|
2017-10-06 |
2024-06-01 |
Amgen Inc |
Drug delivery device with combination assembly and related assembly method
|
EP3694578A1
(en)
|
2017-10-09 |
2020-08-19 |
Amgen Inc. |
Drug delivery device with drive assembly and related method of assembly
|
US11826480B2
(en)
|
2017-11-03 |
2023-11-28 |
Amgen Inc. |
Systems and approaches for sterilizing a drug delivery device
|
US20200338271A1
(en)
|
2017-11-06 |
2020-10-29 |
Amgen Inc. |
Fill-finish assemblies and related methods
|
CA3079197A1
(en)
|
2017-11-06 |
2019-05-09 |
Amgen Inc. |
Drug delivery device with placement and flow sensing
|
CN116832271A
(zh)
|
2017-11-10 |
2023-10-03 |
安进公司 |
用于药物递送装置的柱塞
|
CA3079540A1
(en)
|
2017-11-16 |
2019-05-23 |
Amgen Inc. |
Door latch mechanism for drug delivery device
|
JP2021503311A
(ja)
|
2017-11-16 |
2021-02-12 |
アムジエン・インコーポレーテツド |
失速及び終点検出を有するオートインジェクタ
|
US11781146B2
(en)
|
2018-05-24 |
2023-10-10 |
National University Corporation Hokkaido University |
Vector including a translation-impaired dihydrofolate reductase gene cassette and ubiquitously acting chromatin opening element
|
US10835685B2
(en)
|
2018-05-30 |
2020-11-17 |
Amgen Inc. |
Thermal spring release mechanism for a drug delivery device
|
US11083840B2
(en)
|
2018-06-01 |
2021-08-10 |
Amgen Inc. |
Modular fluid path assemblies for drug delivery devices
|
EP3826699A1
(en)
|
2018-07-24 |
2021-06-02 |
Amgen Inc. |
Delivery devices for administering drugs
|
WO2020023336A1
(en)
|
2018-07-24 |
2020-01-30 |
Amgen Inc. |
Hybrid drug delivery devices with grip portion
|
WO2020023220A1
(en)
|
2018-07-24 |
2020-01-30 |
Amgen Inc. |
Hybrid drug delivery devices with tacky skin attachment portion and related method of preparation
|
CN112469454B
(zh)
|
2018-07-24 |
2024-01-26 |
安进公司 |
用于施用药物的输送装置
|
EP3829692A1
(en)
|
2018-07-31 |
2021-06-09 |
Amgen Inc. |
Fluid path assembly for a drug delivery device
|
MA53724A
(fr)
|
2018-09-24 |
2021-12-29 |
Amgen Inc |
Systèmes et procédés de dosage interventionnel
|
WO2020068476A1
(en)
|
2018-09-28 |
2020-04-02 |
Amgen Inc. |
Muscle wire escapement activation assembly for a drug delivery device
|
CN112805048B
(zh)
|
2018-10-02 |
2023-09-22 |
安进公司 |
具有内部力传递的用于药物递送的注射系统
|
AR116607A1
(es)
|
2018-10-05 |
2021-05-26 |
Amgen Inc |
Dispositivo de administración de fármacos con indicador de dosis
|
SG11202101824VA
(en)
|
2018-10-15 |
2021-03-30 |
Amgen Inc |
Platform assembly process for drug delivery device
|
AR116704A1
(es)
|
2018-10-15 |
2021-06-02 |
Amgen Inc |
Dispositivo de administración de fármacos con mecanismo de amortiguación
|
TWI831847B
(zh)
|
2018-11-01 |
2024-02-11 |
美商安進公司 |
部分針頭縮回之藥物遞送裝置及其操作方法
|
MA54048A
(fr)
|
2018-11-01 |
2022-02-09 |
Amgen Inc |
Dispositifs d'administration de médicament avec rétraction partielle de l'organe d'administration de médicament
|
MA54057A
(fr)
|
2018-11-01 |
2022-02-09 |
Amgen Inc |
Dispositifs d'administration de médicament à rétraction partielle d'élément d'administration de médicament
|
MX2021012557A
(es)
|
2019-04-24 |
2021-11-12 |
Amgen Inc |
Conjuntos y metodos de verificacion de esterilizacion de jeringuillas.
|
CA3148261A1
(en)
|
2019-08-23 |
2021-03-04 |
Amgen Inc. |
Drug delivery device with configurable needle shield engagement components and related methods
|
WO2022159414A1
(en)
|
2021-01-22 |
2022-07-28 |
University Of Rochester |
Erythropoietin for gastroinfestinal dysfunction
|
WO2022246055A1
(en)
|
2021-05-21 |
2022-11-24 |
Amgen Inc. |
Method of optimizing a filling recipe for a drug container
|
WO2023275715A1
(en)
|
2021-06-30 |
2023-01-05 |
Pfizer Inc. |
Metabolites of selective androgen receptor modulators
|
WO2023209074A1
(en)
|
2022-04-28 |
2023-11-02 |
Institut National de la Santé et de la Recherche Médicale |
Methods of restoring erythropoiesis in patients suffering from a sf3b1 mutant myelodysplastic syndrome by correcting coasy mis-splicing
|
WO2024094457A1
(en)
|
2022-11-02 |
2024-05-10 |
F. Hoffmann-La Roche Ag |
Method for producing glycoprotein compositions
|